Knights of Columbus Asset Advisors LLC Has $1.64 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Knights of Columbus Asset Advisors LLC boosted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 104.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 59,424 shares of the biopharmaceutical company’s stock after acquiring an additional 30,309 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in PTC Therapeutics were worth $1,638,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of PTCT. Armistice Capital LLC grew its stake in PTC Therapeutics by 90.0% in the 3rd quarter. Armistice Capital LLC now owns 6,150,000 shares of the biopharmaceutical company’s stock valued at $137,822,000 after buying an additional 2,914,000 shares during the last quarter. Wellington Management Group LLP boosted its holdings in PTC Therapeutics by 39.0% in the 3rd quarter. Wellington Management Group LLP now owns 9,436,188 shares of the biopharmaceutical company’s stock valued at $211,465,000 after purchasing an additional 2,649,824 shares during the period. Norges Bank bought a new stake in PTC Therapeutics in the 4th quarter valued at $24,587,000. State Street Corp boosted its holdings in PTC Therapeutics by 13.8% in the 2nd quarter. State Street Corp now owns 3,624,877 shares of the biopharmaceutical company’s stock valued at $145,213,000 after purchasing an additional 440,850 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in PTC Therapeutics by 33.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,717,765 shares of the biopharmaceutical company’s stock valued at $83,210,000 after purchasing an additional 433,376 shares during the period.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, Director Allan Steven Jacobson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $27.38, for a total value of $273,800.00. Following the completion of the sale, the director now owns 12,348 shares in the company, valued at approximately $338,088.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 13,043 shares of company stock worth $355,650. 5.30% of the stock is currently owned by corporate insiders.

PTC Therapeutics Stock Performance

PTCT opened at $25.32 on Friday. PTC Therapeutics, Inc. has a 1-year low of $17.53 and a 1-year high of $59.84. The firm has a 50-day moving average price of $28.08 and a two-hundred day moving average price of $25.66.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.53). The business had revenue of $307.06 million for the quarter, compared to analysts’ expectations of $315.90 million. As a group, equities research analysts predict that PTC Therapeutics, Inc. will post -5.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. TD Cowen reduced their price target on shares of PTC Therapeutics from $32.00 to $30.00 and set a “market perform” rating for the company in a report on Friday, March 1st. Royal Bank of Canada raised their price objective on shares of PTC Therapeutics from $22.00 to $28.00 and gave the stock a “sector perform” rating in a report on Friday, March 1st. Jefferies Financial Group lifted their price target on shares of PTC Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of PTC Therapeutics in a report on Friday, April 12th. Five equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of “Hold” and an average price target of $33.53.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.